Knop, Filip K.

Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition

Kootte, R. S., Levin, E., Salojärvi, J., Smits, L. P., Hartstra, A. V., Udayappan, S. D., Hermes, G., Bouter, K. E., Koopen, A. M., Holst, J. J., et al. (2017) · Cell Metabolism

Gut microbiota and healthGastrointestinal motility and disorders

Cited by 1,039

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 970

Recovery of gut microbiota of healthy adults following antibiotic exposure

Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., et al. (2018) · Nature Microbiology

Gut microbiota and healthAntibiotic Resistance in Bacteria

Cited by 875

Glucagon-like peptide 1 in health and disease

Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 543

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 431

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 414

Glucose-Dependent Insulinotropic Polypeptide

Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 353

Reduced Incretin Effect in Type 2 Diabetes

Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 349

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 334

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 276

Semaglutide for the treatment of overweight and obesity: A review

Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 265

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 251

Impaired regulation of the incretin effect in patients with type 2 diabetes

Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 219

Glucagon Receptor Signaling and Lipid Metabolism

Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 218

Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies

Kristensen, K., Ögge, L. E., Sengpiel, V., Kjölhede, K., Dotevall, A., Elfvin, A., Knop, F. K., Wiberg, N., Katsarou, A., Shaat, N., et al. (2019) · Diabetologia

Gestational Diabetes Research and ManagementDiabetes Management and Research

Cited by 210

Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 193

Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis

Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J., & Knop, F. K. (2017) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 187

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects

Laursen, T. L., Hagemann, C. A., Wei, C., Kazankov, K., Thomsen, K. L., Knop, F. K., & Grønbæk, H. (2019) · World Journal of Hepatology

Liver Disease Diagnosis and TreatmentBariatric Surgery and Outcomes

Cited by 176

Metformin-Induced Glucagon-Like Peptide-1 Secretion Contributes to the Actions of Metformin in Type 2 Diabetes

Bahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., et al. (2018) · JCI Insight

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 173

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease

Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 168

The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 162

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 158

Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

Storgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 155

Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis

Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism

Schizophrenia research and treatmentPharmacology and Obesity Treatment

Cited by 144